Compare Bristol-Myers Squibb Co (BMY) vs MobilEye Global Inc (MBLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs MobilEye Global Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.77 (market cap $129.94B), while MobilEye Global Inc trades at $8.82 (market cap $7.54B). The key difference: Bristol-Myers Squibb Co is far larger — about 17.2× MobilEye Global Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while MobilEye Global Inc pays none. Which is the better fit depends on your goals.
| BMY | MBLY | |
|---|---|---|
Market Cap | $129.94B | $7.54B |
Sector | Health | Technology |
52-Week High | $65.89 | $15.54 |
52-Week Low | $42.60 | $6.56 |
Enterprise Value | $163.92B | $6.10B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Mobileye Global Inc. (MBLY) trades at $8.77, up 0.23% on the day, with a bullish technical signal driven by moving averages. The stock shows strong earnings beats in recent quarters, with Q2 2026 EPS of $0.19 surpassing expectations, but faces fundamental challenges with a net income margin of -201.49% in 2026. Recent news highlights CEO transition and expanded partnerships, such as the Stellantis ADAS supply deal announced July 21, 2026.
The outlook is mixed: analyst consensus is bullish with a $11.40 price target (61.54% buy ratings), but high valuation (EV/EBITDA 43.25) and profitability risks persist. Investment opportunity lies in autonomous driving growth, while key risks include leadership uncertainty and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About MobilEye Global Inc
Mobileye Global Inc. is a global leader in the development and deployment of Advanced Driver Assistance Systems (ADAS) and autonomous driving technologies. The company specializes in computer vision, machine learning, and data analysis to create sensing, mapping, and driving policy solutions. Mobileye's technology, including its EyeQ system-on-chips and its crowd-sourced mapping platform (REM), is integrated into vehicles worldwide, aiming to improve road safety and enable the future of autonomous mobility.
Read more on MBLY →
